多数Graves病患者有着不同程度的眼部受累 ,其中 3%～ 5 %的患者出现严重的Graves眼病 ,但目前该眼病的治疗效果仍不理想。近年的研究表明长效生长抑素类似物奥曲肽和兰瑞肽可以有效治疗Graves眼病。其确切机制仍不清楚 ,可能是通过抑制胰岛素样生长因子 Ⅰ的活性 ,或直接抑制T淋巴细胞释放细胞因子 ,还可能通过特异性的细胞表面生长抑素受体作用于靶细胞 Most patients with Graves’ disease have varying degrees of ocular involvement. Among them, 3% to 5% of patients have severe Graves ophthalmopathy, but the current treatment of this disease is still not satisfactory. Recent studies have shown that long-acting somatostatin analogues octreotide and lanreotide can effectively treat Graves ophthalmopathy. The exact mechanism remains unclear, possibly by inhibiting the activity of insulin-like growth factor I, or directly inhibiting the release of cytokines by T lymphocytes and possibly by targeting specific cell surface somatostatin receptors